Skip to Main Content

Two patients with advanced Hodgkin lymphoma were told their tumors were so resistant to treatment that hospice was their best option. Then, they were enrolled in a clinical trial of a novel immunotherapy involving so-called natural killer cells. After treatment, they saw complete remission.

Researchers say the results, detailed in data released Friday, are a hopeful if preliminary sign of the potential of immunotherapies harnessing natural killer, or NK, cells — innate immune system cells that have certain advantages over the more commonly recognized adaptive T cell cancer therapies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!